0A8L Stock Overview A precision medicine company, develops and commercializes molecular microbiology solutions for life threatening infectious diseases in the United States and internationally. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for OpGen Historical stock prices Current Share Price US$0.66 52 Week High US$9.87 52 Week Low US$0.66 Beta -0.62 1 Month Change -58.49% 3 Month Change -66.83% 1 Year Change -84.99% 3 Year Change -99.70% 5 Year Change n/a Change since IPO -99.87%
Recent News & Updates
OpGen, Inc. announced delayed 10-Q filing Nov 15 OpGen Receives a Letter from the Nasdaq Hearings Panel Determines to Deny its Request for Continued Listing on Nasdaq
OpGen, Inc.(OTCPK:OPGN) dropped from S&P TMI Index Aug 22
OpGen, Inc.(OTCPK:OPGN) dropped from NASDAQ Composite Index Aug 21
OpGen, Inc. announced delayed 10-Q filing Aug 15
OpGen Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on Nasdaq Jun 13 See more updates
OpGen, Inc. announced delayed 10-Q filing Nov 15 OpGen Receives a Letter from the Nasdaq Hearings Panel Determines to Deny its Request for Continued Listing on Nasdaq
OpGen, Inc.(OTCPK:OPGN) dropped from S&P TMI Index Aug 22
OpGen, Inc.(OTCPK:OPGN) dropped from NASDAQ Composite Index Aug 21
OpGen, Inc. announced delayed 10-Q filing Aug 15
OpGen Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on Nasdaq Jun 13
Nasdaq Hearings Panel Grants Extension to OpGen, to Regain Compliance by July 8, 2024 Jun 05
OpGen Receives Notice from Nasdaq Regarding Non-Compliance with Nasdaq Listing Rule 5250(c)(1) Due to Not Filing its Quarterly Report on Form 10-Q for the Period Ended March 31, 2024 May 25 OpGen, Inc. announced delayed 10-Q filing May 18
OpGen, Inc. Announces 1-For-10 Reverse Stock Split to Regain Compliance with the Nasdaq Capital Market’s Minimum Bid Price Listing Requirement of $1.00 Per Share May 17
OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K Apr 24 OpGen, Inc. announced delayed annual 10-K filing Mar 30
Opgen, Inc. Announces Chief Executive Officer Changes
New major risk - Revenue and earnings growth Mar 22
OpGen Submits A Request for A Hearing Before the Panel, Which Request Stayed Any Suspension or Delisting Action by Nasdaq At Least Until the Hearing Process Concludes and Any Extension Granted by the Panel Expires Dec 13
Third quarter 2023 earnings released: US$0.46 loss per share (vs US$5.92 loss in 3Q 2022) Nov 17 OpGen, Inc. announced that it expects to receive $1 million in funding Oct 12
OpGen, Inc. to Report Q2, 2023 Results on Aug 10, 2023 Aug 04
OpGen Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement Jun 12
OpGen, Inc. to Report Q1, 2023 Results on May 15, 2023 May 09 OpGen, Inc. has completed a Follow-on Equity Offering in the amount of $3.5 million. May 06
OpGen, Inc. Announces Preliminary Unaudited Revenue for 2022 Jan 19 OpGen, Inc. has completed a Follow-on Equity Offering in the amount of $7.5 million. Jan 09
OpGen, Inc Announces Positive Top Line Data from Clinical Trial for Unyvero Urinary Tract Infection Panel Dec 14 OpGen, Inc. Reports Goodwill Impairment Charge for the Third Quarter Ended September 30, 2022
OpGen, Inc. to Report Q3, 2022 Results on Nov 10, 2022 Oct 29
OpGen, Inc. to Report Q3, 2022 Results on Nov 10, 2022 Oct 28 OpGen, Inc. has completed a Follow-on Equity Offering in the amount of $3.38 million. Oct 05
OpGen, Inc. Announces Successful Completion of Clinical Trial Enrollment for Unyvero Urinary Tract Infection Panel Oct 04
Nasdaq Grants OpGen 180-Day Extension to Meet Minimum Bid Price Requirement Sep 01
Opgen, Inc. Launches Ares Sequencing Services in the U.S. from Its Rockville, Maryland Laboratory Aug 26
OpGen, Inc. Provides Revenue Guidance for Fiscal Year 2022 Aug 12
OpGen, Inc. to Report Q2, 2022 Results on Aug 11, 2022 Jul 29 OpGen, Inc. Announces Publication of Results of Unyvero Hospitalized Pneumonia (Hpn) Panel for Detection of Bacterial Respiratory Tract Pathogens from Serial Specimens Collected from Hospitalized Covid-19 Patients
OpGen, Inc. Announces Publication of Results from Major Clinical Study Using Unyvero Hospitalized Pneumonia Panel in the Lancet Respiratory Medicine May 27
OpGen, Inc. Provides Earnings Guidance for the Year 2022 May 14
OpGen, Inc., Annual General Meeting, Jun 09, 2022 Apr 26
OpGen, Inc. Announces Interim Analysis Results from Clinical Trial for Unyvero Urinary Tract Infection Panel Apr 06
OpGen, Inc. Provides Revenue Guidance for the Year 2022 Mar 30
OpGen, Inc. Announces Publication of Results from the Acuitas AMR Gene Panel Multicenter Clinical Trial in the Journal of Clinical Microbiology Feb 11
OpGen, Inc. Submits Updated 510(k) Summary to FDA For Acuitas AMR Gene Panel for Isolates Jun 08
First quarter 2021 earnings released: US$0.50 loss per share (vs US$0.53 loss in 1Q 2020) May 14 Shareholder Returns 0A8L GB Biotechs GB Market 7D -34.0% -5.0% -1.9% 1Y -85.0% -24.4% 2.6%
See full shareholder returns
Return vs Industry: 0A8L underperformed the UK Biotechs industry which returned -24.5% over the past year.
Return vs Market: 0A8L underperformed the UK Market which returned 2.4% over the past year.
Price Volatility Is 0A8L's price volatile compared to industry and market? 0A8L volatility 0A8L Average Weekly Movement n/a Biotechs Industry Average Movement 6.9% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.7% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine 0A8L's volatility change over the past year.
About the Company OpGen, Inc., a precision medicine company, develops and commercializes molecular microbiology solutions for life threatening infectious diseases in the United States and internationally. The company’s products include Unyvero application cartridges, Unyvero systems, Acuitas AMR Gene Panel test products, and SARS CoV-2 test kits. It provides laboratory services; collaboration services, including funded software arrangements; and license arrangements services.
Show more OpGen, Inc. Fundamentals Summary How do OpGen's earnings and revenue compare to its market cap? 0A8L fundamental statistics Market cap US$7.29m Earnings (TTM ) -US$9.92m Revenue (TTM ) US$1.27m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0A8L income statement (TTM ) Revenue US$1.27m Cost of Revenue US$1.59m Gross Profit -US$323.88k Other Expenses US$9.59m Earnings -US$9.92m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.99 Gross Margin -25.59% Net Profit Margin -783.50% Debt/Equity Ratio 0%
How did 0A8L perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 13:43 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources OpGen, Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Benjamin Haynor Alliance Global Partners null null Brookline Capital Markets Nidhi Singh Edison Investment Research
Show 3 more analysts 